[go: up one dir, main page]

WO2006105168A3 - Enhancing immune responses with bacterial exotoxins - Google Patents

Enhancing immune responses with bacterial exotoxins Download PDF

Info

Publication number
WO2006105168A3
WO2006105168A3 PCT/US2006/011423 US2006011423W WO2006105168A3 WO 2006105168 A3 WO2006105168 A3 WO 2006105168A3 US 2006011423 W US2006011423 W US 2006011423W WO 2006105168 A3 WO2006105168 A3 WO 2006105168A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune responses
enhancing immune
bacterial exotoxins
methods
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/011423
Other languages
French (fr)
Other versions
WO2006105168A2 (en
Inventor
Patrick M Schlievert
Marnie L Peterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota Twin Cities
University of Minnesota System
Original Assignee
University of Minnesota Twin Cities
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota Twin Cities, University of Minnesota System filed Critical University of Minnesota Twin Cities
Publication of WO2006105168A2 publication Critical patent/WO2006105168A2/en
Publication of WO2006105168A3 publication Critical patent/WO2006105168A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/06—Uses of viruses as vector in vitro

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention features methods of enhancing immune responses, methods of increasing expression of major histocompatibility complex (MHC) class I molecules on the surface of cells, and methods of delivering antigens or antigenic peptides to the cytoplasm of cells.
PCT/US2006/011423 2005-03-29 2006-03-28 Enhancing immune responses with bacterial exotoxins Ceased WO2006105168A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66646605P 2005-03-29 2005-03-29
US60/666,466 2005-03-29

Publications (2)

Publication Number Publication Date
WO2006105168A2 WO2006105168A2 (en) 2006-10-05
WO2006105168A3 true WO2006105168A3 (en) 2006-12-14

Family

ID=37054069

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/011423 Ceased WO2006105168A2 (en) 2005-03-29 2006-03-28 Enhancing immune responses with bacterial exotoxins

Country Status (1)

Country Link
WO (1) WO2006105168A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230099956A (en) * 2021-12-28 2023-07-05 제이더블유크레아젠 주식회사 Polypeptide for Delivering Antigen to Immune Cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092894A1 (en) * 1996-03-29 2003-05-15 Pharmacia Ab, Uppsala Sweden Modified chimeric superantigens and their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092894A1 (en) * 1996-03-29 2003-05-15 Pharmacia Ab, Uppsala Sweden Modified chimeric superantigens and their use

Also Published As

Publication number Publication date
WO2006105168A2 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
WO2009133378A3 (en) Products and methods for stimulating an immune response
WO2008118587A3 (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
NO20092052L (en) Antibodies and immune conjugates, and uses thereof
WO2008103947A3 (en) Activation of human antigen-presenting cells through clec-6
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
MX2021007368A (en) Anti-transferrin receptor antibodies and uses thereof.
NO20085396L (en) Antibodies and immune conjugates, and uses thereof
WO2009128949A3 (en) Compositions of dengue viral proteins and methods of use
EP4364754A3 (en) Anti-b7-h3 antibodies and antibody drug conjugates
WO2007140472A3 (en) Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs
MX2009001412A (en) Protein matrix vaccines and methods of making and administering such vaccines.
WO2008100598A3 (en) A method for enhancing t cell response
NO20084356L (en) Anti TAT226 antibodies and immunoconjugates
WO2011005799A3 (en) Rna containing modified nucleotides and use thereof in vaccines
WO2009067349A3 (en) Modulation of the immune response
MY160201A (en) Immunostimulatory oligonucleotides
MY148763A (en) Anti-5t4 antibodies and uses thereof
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
EP1594536A4 (en) Adjuvanted influenza vaccine
EP4349864A3 (en) Oncostatin m receptor antigen binding proteins
EA200900738A1 (en) SLIP PROTEINS CONTAINING ANTIGENS OF TUMOR TENSIONS NY-ESO-1 AND LAGE-1
WO2010056144A3 (en) Foxp3+ natural kiler t-cells and the treatment of immune related diseases
HK1201176A1 (en) Antigen presenting cancer vaccine
WO2008080091A3 (en) Activation of rig-i pathway
WO2009149021A3 (en) Xbp1, cd138, and cs1 peptides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06748865

Country of ref document: EP

Kind code of ref document: A2